-
1
-
-
0037019586
-
Relationship between obesity, insulin resistance, and coronary heart disease risk
-
Abbasi F., Brown B.W.B., Lamendola C., McLaughlin T., and Reaven G.M. Relationship between obesity, insulin resistance, and coronary heart disease risk. Journal of American College of Cardiology 40 (2002) 937-943
-
(2002)
Journal of American College of Cardiology
, vol.40
, pp. 937-943
-
-
Abbasi, F.1
Brown, B.W.B.2
Lamendola, C.3
McLaughlin, T.4
Reaven, G.M.5
-
2
-
-
0842348094
-
-
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity
-
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
-
(2004)
Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care
, vol.27
, pp. 596-601
-
-
-
3
-
-
33244486544
-
Diagnosis and classification of diabetes mellitus
-
American Diabetes Association Professional Practice Committee
-
American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(Suppl. 1):S43-8.
-
(2006)
Diabetes Care
, vol.29
, Issue.SUPPL. 1
-
-
-
4
-
-
30144440088
-
Drugs and the treatment of psychiatric disorders, antipsychotic and antimanic agents
-
Hardman J.P., Limbird L.E., and Gillman A.G. (Eds), McGraw Hill, New York [chapter 18]
-
Baldessarini R.J., and Tarzi F.I. Drugs and the treatment of psychiatric disorders, antipsychotic and antimanic agents. In: Hardman J.P., Limbird L.E., and Gillman A.G. (Eds). Goodman and Gillman's the pharmacological basis of therapeutics. 11th ed. (2005), McGraw Hill, New York [chapter 18]
-
(2005)
Goodman and Gillman's the pharmacological basis of therapeutics. 11th ed.
-
-
Baldessarini, R.J.1
Tarzi, F.I.2
-
5
-
-
26444456116
-
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia
-
Breier A., Berg P.H., Thakore J.H., Naber D., Gattaz W.F., Cavazzoni P., et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. American Journal of Psychiatry 162 (2005) 1879-1887
-
(2005)
American Journal of Psychiatry
, vol.162
, pp. 1879-1887
-
-
Breier, A.1
Berg, P.H.2
Thakore, J.H.3
Naber, D.4
Gattaz, W.F.5
Cavazzoni, P.6
-
6
-
-
0035897696
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
Executive Summary of the Third Report of the National Cholesterol Education Program NCEP
-
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001;285:2486-97.
-
(2001)
Journal of the American Medical Association
, vol.285
, pp. 2486-2497
-
-
-
8
-
-
33646681652
-
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
-
Kinon B.J., Lipkovich I., Edwards S.B., Adams D.H., Ascher-Svanum H., and Siris S.G. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. Journal of Clinical Psychopharmacology 26 (2006) 157-162
-
(2006)
Journal of Clinical Psychopharmacology
, vol.26
, pp. 157-162
-
-
Kinon, B.J.1
Lipkovich, I.2
Edwards, S.B.3
Adams, D.H.4
Ascher-Svanum, H.5
Siris, S.G.6
-
9
-
-
0034977454
-
How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors
-
Kraemer H.C., Stice E., Kazdin A., Offord D., and Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. American Journal of Psychiatry 158 (2001) 848-856
-
(2001)
American Journal of Psychiatry
, vol.158
, pp. 848-856
-
-
Kraemer, H.C.1
Stice, E.2
Kazdin, A.3
Offord, D.4
Kupfer, D.5
-
11
-
-
25144456112
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
-
Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
-
(2005)
New England Journal of Medicine
, vol.353
, pp. 1209-1223
-
-
Lieberman, J.A.1
Stroup, T.S.2
McEvoy, J.P.3
-
12
-
-
3342901698
-
Physical health monitoring of patients with schizophrenia
-
Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Case D.E., Davis J.M., et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161 (2004) 1334-1349
-
(2004)
American Journal of Psychiatry
, vol.161
, pp. 1334-1349
-
-
Marder, S.R.1
Essock, S.M.2
Miller, A.L.3
Buchanan, R.W.4
Case, D.E.5
Davis, J.M.6
-
13
-
-
0037016001
-
Differentiation between obesity and insulin resistance in the association with C-reactive protein
-
McLaughlin T., Abbasi F., Lamendola C., et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106 (2002) 2908-2912
-
(2002)
Circulation
, vol.106
, pp. 2908-2912
-
-
McLaughlin, T.1
Abbasi, F.2
Lamendola, C.3
-
14
-
-
0003135770
-
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults
-
National Institutes of Health, Bethesda, MD: National Institutes of Health, United States Department of Health and Human Services;
-
National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the Evidence Report. Bethesda, MD: National Institutes of Health, United States Department of Health and Human Services; 1998.
-
(1998)
the Evidence Report
-
-
-
15
-
-
2342430250
-
Obesity, insulin resistance, and cardiovascular disease
-
Reaven G.M. Obesity, insulin resistance, and cardiovascular disease. Recent Progress in Hormone Research 59 (2004) 207-223
-
(2004)
Recent Progress in Hormone Research
, vol.59
, pp. 207-223
-
-
Reaven, G.M.1
-
16
-
-
14744293406
-
Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals
-
Reaven G.M. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinology and Metabolism Clinics of North America 34 (2005) 49-62
-
(2005)
Endocrinology and Metabolism Clinics of North America
, vol.34
, pp. 49-62
-
-
Reaven, G.M.1
-
17
-
-
0024160877
-
Role of insulin resistance in human disease
-
Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
-
(1988)
Diabetes
, vol.37
, pp. 1595-1607
-
-
Reaven, G.M.1
-
18
-
-
0037418543
-
Identifying the overweight patient who will benefit the most by losing weight
-
Reaven G.M. Identifying the overweight patient who will benefit the most by losing weight. Annals of Internal Medicine 138 (2003) 420-423
-
(2003)
Annals of Internal Medicine
, vol.138
, pp. 420-423
-
-
Reaven, G.M.1
-
19
-
-
0033527030
-
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT)
-
Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT). New England Journal of Medicine 341 (2005) 410-418
-
(2005)
New England Journal of Medicine
, vol.341
, pp. 410-418
-
-
Rubins, H.B.1
Robins, S.J.2
Collins, D.3
-
20
-
-
23344434378
-
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia
-
Simpson G.M., Weiden P., Pigott T., Murray S., Siu C.O., and Romano S.J. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. American Journal of Psychiatry 162 (2005) 1535-1538
-
(2005)
American Journal of Psychiatry
, vol.162
, pp. 1535-1538
-
-
Simpson, G.M.1
Weiden, P.2
Pigott, T.3
Murray, S.4
Siu, C.O.5
Romano, S.J.6
-
21
-
-
0033984997
-
Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic individuals
-
Yeni-Komshian H., Carantoni M., Abbasi F., and Reaven G.M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic individuals. Diabetes Care 23 (2000) 171-175
-
(2000)
Diabetes Care
, vol.23
, pp. 171-175
-
-
Yeni-Komshian, H.1
Carantoni, M.2
Abbasi, F.3
Reaven, G.M.4
|